+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Fibrodysplasia Ossificans Progressiva Market by Offering (Drug Type, Treatment), Route of Administration (Oral, Parenteral, Topical), End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 194 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5968134
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Fibrodysplasia Ossificans Progressiva Market grew from USD 470.46 million in 2023 to USD 494.59 million in 2024. It is expected to continue growing at a CAGR of 5.30%, reaching USD 675.65 million by 2030.

This process leads to bone-forming outside the skeleton, restricting movement. The disorder is caused by a mutation in the ACVR1 gene, which impacts the body's repair mechanism, causing fibrous tissues to be replaced by bone after damage or injury. Rising fibrodysplasia ossificans progressiva incidence rates worldwide are expanding the need for treatments associated with fibrodysplasia ossificans progressiva. The elevating awareness among healthcare professionals and the public, with increased funding and support from government bodies for rare diseases, is improving diagnostics and the availability of treatment options, subsequently supporting market growth. High R&D costs for developing effective treatments for FOP and stringent regulatory processes for approving drugs for rare diseases are hampering the market's growth. Increasing progress in genetic research and targeted therapy approaches that offer potential breakthrough treatments associated with fibrodysplasia ossificans progressiva creates opportunities for market growth.

Regional Insights

The market for fibrodysplasia ossificans progressiva (FOP) in the Americas is characterized by a robust research and development ecosystem, benefiting from advanced healthcare infrastructure and a strong emphasis on rare disease treatment. There are also multiple awareness programs and patient advocacy groups that support research funding and patient care. Regulatory incentives such as orphan drug designation by the FDA expedite the approval process for new treatments, making the Americas a critical region for FOP therapeutic development and commercialization. Asia-Pacific is witnessing a growing awareness and increasing diagnosis rates of rare diseases, including FOP. This market is gradually evolving with improved healthcare systems and increased healthcare spending in countries including China, Japan, and Australia. However, challenges such as limited access to treatment and a lack of specialized healthcare facilities for rare diseases prevail. The EMEA region's FOP market is diverse, with Europe leading in clinical research, drug development, and patient advocacy. European countries benefit from strong public healthcare systems and policies encouraging rare disease research, including substantial funding and incentives for orphan drug development. Collaborations between governments, research institutions, and pharmaceutical companies support the market. In contrast, the Middle East and Africa face more profound challenges, including lower awareness, scant research, and limited treatment access. However, ongoing efforts to establish better healthcare infrastructure and international collaborations for rare disease treatment are positive indicators for the market's future in African regions.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Fibrodysplasia Ossificans Progressiva Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Growing incidence of fibrodysplasia ossificans progressiva diseases
  • Rising awareness among healthcare professionals and the public for rare and genetic diseases

Market Restraints

  • High cost of development of fibrodysplasia ossificans progressiva treatment

Market Opportunities

  • Rising research & development activities to develop novel fibrodysplasia ossificans progressiva treatments
  • Availability of government funding and approvals for rare diseases

Market Challenges

  • Limited awareness for the fibrodysplasia ossificans progressiva

Market Segmentation Analysis

  • Offering: Rising need for palovarotene for reducing the progression of heterotopic ossification in FOP
  • End-User: High usage of fibrodysplasia ossificans progressiva drugs in hospitals for diagnosis, treatment, and ongoing management of FOP

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Fibrodysplasia Ossificans Progressiva Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Fibrodysplasia Ossificans Progressiva Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Ipsen Fibrodysplasia Ossificans Progressiva Treatment

Ipsen received FDA approval for Sohonos (palovarotene), a novel treatment aimed at combating fibrodysplasia ossificans progressiva (FOP). This marks a significant milestone as Sohonos stands as the first and only FDA-approved therapy for FOP, a rare and debilitating disorder that affects roughly 400 individuals in the U.S. and 900 worldwide. Sohonos, an oral medication, specifically targets the gamma subtype of retinoic-acid receptors involved in skeletal development and ectopic bone formation, offering hope to adult and pediatric patients (females aged eight and older, males aged 10 and older) by significantly reducing the volume of new heterotopic ossification (HO) - the abnormal bone growth that characterizes FOP and severely limits mobility and function. This approval not only underscores Ipsen's commitment to addressing unmet medical needs but also represents a transformative advancement in treating FOP.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Fibrodysplasia Ossificans Progressiva Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Fibrodysplasia Ossificans Progressiva Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Accord Healthcare, Inc, Amgen Inc., BioCryst Pharmaceuticals, Inc., bioMérieux S.A., Blueprint Medicines Corporation, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Incyte Corporation, Ipsen Pharma, Merck & Co Inc., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Fibrodysplasia Ossificans Progressiva Market to forecast the revenues and analyze trends in each of the following sub-markets:

Offering- Drug Type

  • Anti-inflammatory Medications
  • Bisphosphonates
  • Corticosteroids
  • Palovarotene

Treatment

  • Medication
  • Occupational Therapy
  • Surgery

Route of Administration

  • Oral
  • Parenteral
  • Topical

End-User

  • Hospitals
  • Research Institutes
  • Specialty Clinics

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidence of fibrodysplasia ossificans progressiva diseases
5.1.1.2. Rising awareness among healthcare professionals and the public for rare and genetic diseases
5.1.2. Restraints
5.1.2.1. High cost of development of fibrodysplasia ossificans progressiva treatment
5.1.3. Opportunities
5.1.3.1. Rising research & development activities to develop novel fibrodysplasia ossificans progressiva treatments
5.1.3.2. Availability of government funding and approvals for rare diseases
5.1.4. Challenges
5.1.4.1. Limited awareness for the fibrodysplasia ossificans progressiva
5.2. Market Segmentation Analysis
5.2.1. Offering: Rising need for palovarotene for reducing the progression of heterotopic ossification in FOP
5.2.2. End-User: High usage of fibrodysplasia ossificans progressiva drugs in hospitals for diagnosis, treatment, and ongoing management of FOP
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Fibrodysplasia Ossificans Progressiva Market, by Offering
6.1. Introduction
6.2. Drug Type
6.3. Treatment
7. Fibrodysplasia Ossificans Progressiva Market, by Route of Administration
7.1. Introduction
7.2. Oral
7.3. Parenteral
7.4. Topical
8. Fibrodysplasia Ossificans Progressiva Market, by End-User
8.1. Introduction
8.2. Hospitals
8.3. Research Institutes
8.4. Specialty Clinics
9. Americas Fibrodysplasia Ossificans Progressiva Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Fibrodysplasia Ossificans Progressiva Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Fibrodysplasia Ossificans Progressiva Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. FDA Approves Ipsen Fibrodysplasia Ossificans Progressiva Treatment
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET RESEARCH PROCESS
FIGURE 2. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET DYNAMICS
FIGURE 7. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
FIGURE 8. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PALOVAROTENE, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PALOVAROTENE, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY MEDICATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY MEDICATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 48. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 49. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 50. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 53. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 54. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 59. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 60. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 61. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 62. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 63. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 64. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 65. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 66. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 67. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 68. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 69. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 70. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 71. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 72. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 73. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 74. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 75. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 76. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 77. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 78. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 79. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 80. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 81. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 82. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 83. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 84. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 85. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 86. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 87. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 88. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 89. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 90. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 91. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 92. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 93. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 94. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 95. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 96. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 97. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 98. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 99. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 100. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 101. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 102. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 103. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 104. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 105. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 106. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 107. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 108. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 109. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 110. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 112. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 114. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 116. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 118. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 120. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 122. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 123. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 124. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 125. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 126. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 127. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 128. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 129. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 130. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 131. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 132. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 133. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 134. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 135. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 136. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 137. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 138. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 139. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 140. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 141. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 142. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 143. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 144. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 145. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 146. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 147. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 148. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 149. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 150. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 151. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 152. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 153. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 154. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 155. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 156. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 157. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 158. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 159. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 160. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 161. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 162. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 163. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 164. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 165. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 166. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 167. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 168. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 169. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 170. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 171. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 172. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 173. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 174. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 175. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 176. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 177. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 178. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 179. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 180. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 181. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 182. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 183. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 184. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 185. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 186. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 187. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 188. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 189. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 190. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 191. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 192. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 193. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 194. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 195. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 196. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 197. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 198. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 199. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 200. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 201. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 202. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 203. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 204. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 205. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 206. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 207. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 208. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 209. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 210. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 211. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 212. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 213. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 214. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 215. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 216. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 217. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 218. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 219. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 220. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 221. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 222. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 223. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 224. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 225. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 226. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 227. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 228. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 229. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 230. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 231. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 232. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 233. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 234. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 235. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 236. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 237. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 238. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 239. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 240. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 241. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 242. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 255. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 256. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 257. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 258. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 259. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 260. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 261. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 262. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 263. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 264. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 265. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 266. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 267. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 268. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 269. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 270. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 271. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 272. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 273. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 274. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 275. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 276. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 277. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 278. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 279. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 280. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 281. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 282. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 283. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 284. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 285. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 286. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 287. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 288. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 289. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 290. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 291. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 292. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 293. FRANCE FI

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbvie Inc.
  • Accord Healthcare, Inc
  • Amgen Inc.
  • BioCryst Pharmaceuticals, Inc.
  • bioMérieux S.A.
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company, Limited
  • Incyte Corporation
  • Ipsen Pharma
  • Merck & Co Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 494.59 Million
Forecasted Market Value ( USD ) by 2030 $ 675.65 Million
Compound Annual Growth Rate5.3%
Regions CoveredGlobal

Related Topics

Related Reports

Fibrodysplasia Ossificans Progressiva (FOP) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Fibrodysplasia Ossificans Progressiva (FOP) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Fibrodysplasia Ossificans Progressiva Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Fibrodysplasia Ossificans Progressiva Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 138 Pages
  • Global
From
Fibrodysplasia ossificans progressiva - Pipeline Insight, 2024 - Product Image

Fibrodysplasia ossificans progressiva - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Fibrodysplasia Ossificans Progressiva Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Fibrodysplasia Ossificans Progressiva Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 86 Pages
  • Global
From
Skeletal Dysplasia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Skeletal Dysplasia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 175 Pages
  • Global
From

About the Fibrodysplasia Ossificans Progressiva Market

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, genetic disorder of the connective tissue that causes muscle tissue and connective tissue such as tendons and ligaments to be gradually replaced by bone, forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Musculoskeletal Disorders Drugs are used to treat FOP, including bisphosphonates, which are used to reduce the activity of cells that cause the formation of extra-skeletal bone, and corticosteroids, which are used to reduce inflammation. Other treatments include physical therapy, occupational therapy, and surgery. Companies in the FOP market include Novartis, which produces the bisphosphonate Aclasta, and Pfizer, which produces the corticosteroid Xeljanz. Other companies include Sanofi, which produces the bisphosphonate Zometa, and Regeneron, which produces the bisphosphonate Arcalyst. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.